Helius Medical Technologies Inc Class A (HSDT) Stock Forecast & Price Target
Helius Medical Technologies Inc Class A · NASDAQ
$1.69+0.01 (+0.60%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Helius Medical Technologies Inc Class A, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 137% above the current $1.69. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $-0.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Helius Medical Technologies Inc Class A.
As of Jul, 1 of 1 firms rate HSDT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HSDT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.02 – $-0.01 · 2 analysts
Next period, 2 analysts expect Helius Medical Technologies Inc Class A to earn $-0.01 a share (range $-0.02 – $-0.01), versus — a year earlier. Full-year consensus is $-0.72, growing to $-0.06 the year after.
REVENUE · NEXT QUARTER
$3.5M
Range $3.2M – $3.8M · 2 analysts · +402% YoY
Revenue is expected to reach $3.5M (range $3.2M – $3.8M), +402.2% year-over-year. Full-year consensus is $14.2M, rising to $14.8M next year.
Top analysts covering Helius Medical Technologies Inc Class A
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HSDT.
#1
Anthony Vendetti
Maxim Group · Rank #281
Hold
No targeton HSDT
Overall win rate
30%
+ Follow
#2
Matthew Galinko
Maxim Group · Rank #357
Buy
$4.00+136.7% to target
Overall win rate
24%
+ Follow
#3
FS
Fedor Shabalin
B. Riley Securities
Buy
$3.00+77.5% to target
Coverage
—
+ Follow
HSDT stock forecast FAQ
What is HSDT's average 12-month price target?+
The 1 analysts with a live target average $4.00 for Helius Medical Technologies Inc Class A over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is HSDT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HSDT?+
1 analysts have an active rating on Helius Medical Technologies Inc Class A, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering HSDT?+
Among analysts who currently cover HSDT, Anthony Vendetti of Maxim Group has the strongest overall Quantellect track record (Rank #281). Their current call is Hold.
What is Helius Medical Technologies Inc Class A's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.02 – $-0.01) across 2 analysts. Full-year EPS is projected at $-0.72, rising to $-0.06 the following year.
How much revenue is Helius Medical Technologies Inc Class A expected to report next quarter?+
Consensus revenue is $3.5M (range $3.2M – $3.8M). Full-year revenue is projected at $14.2M, growing to $14.8M next year.
Have analysts been upgrading or downgrading HSDT lately?+
As of Jul, 1 of 1 firms rate HSDT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HSDT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
